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Abstract
Introduction: Inactivating mutations in CYP24A1, encoding vitamin D-24-hydroxylase, can 
lead to an accumulation of active vitamin D metabolites and consequent hypercalcaemia. 
Patient (infantile and adult) presentation is varied and includes mild-severe 
hypercalcaemia, hypercalciuria, nephrocalcinosis and nephrolithiasis. This study aimed 
to characterize the clinical and biochemical phenotypes of a family with two CYP24A1 
missense variants.
Methods: The proband and seven family members underwent detailed clinical and 
biochemical evaluation. Laboratory measurements included serum calcium, intact 
parathyroid hormone (iPTH), vitamin D metabolites and urine calcium and creatinine.
Results: The proband presented during the second trimester of a planned pregnancy with 
flu-like symptoms. Laboratory tests showed elevated adjusted calcium of 3.27 (upper 
reference limit (URL: 2.30) mmol/L), suppressed iPTH (<6 ng/L), elevated 25(OH)D (264 
(URL: 55) nmol/L) and elevated 1,25(OH)D (293 (URL: <280) pmol/L). Ionized calcium 
was 1.55 (URL: 1.28) mmol/L. Sanger sequencing revealed two heterozygous missense 
variants in the CYP24A1: p.(Arg439Cys), R439C and p.(Trp275Arg), W275R. The proband’s 
brother and sister had the same genotype. The brother had intermittent hypercalcaemia 
and hypervitaminosis D. Only the sister had a history of nephrolithiasis. The proband’s 
daughter and two nephews were heterozygous for the R439C variant. The proband and 
her brother frequently had elevated 25(OH)D:24,25(OH)2D ratios (>50) during follow-up. 
Conclusions: W275R is a new pathogenic CYP24A1 mutation in compound heterozygotic 
form with R439C in this family.
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Introduction
Vitamin D is a fat soluble vitamin (1) essential for 
calcium and phosphate homeostasis, bone metabolism 
(2) and possibly the prevention of chronic diseases 
such as cardiovascular disease and cancer (3). Vitamin 
D is obtained when 7-dehydrocholesterol in the skin is 
exposed to UV B (UVB) radiation (vitamin D3) and from 
diet and/or dietary supplements (primarily vitamin D2 but 
also vitamin D3) (4). Vitamin D3, by itself, is not an active 
substance and must first undergo a series of reactions in 
the liver and kidneys to generate the active form (5). In the 
liver, vitamin D3 is hydroxylated to form the prehormone 
25-hydroxycholecalciferol D (25(OH)D3) catalysed 
primarily by CYP2R1 with CYP27A1 possibly contributing 
(6). 25(OH)D3 is then transported to the proximal tubules 
of the kidney bound to vitamin D binding protein where it is 
hydroxylated to form the active 1,25-dihydroxyvitamin D3 
(1,25(OH)2D3), catalysed by CYP27B1. Finally, 25(OH)D3  
and 1,25(OH)2D3 are catabolised by CYP24A1, a key 
physiological regulator, to form 24,25-dihydroxyvitamin 
D3 (24,25(OH)2D3) and 1,24,25-trihydroxyvitamin D3 
(1,24,25(OH)3D3) (Supplementary Fig. 1, see section 
on supplementary materials given at the end of this 
article), the first step toward the final inactive end 
product, calcitroic acid, which is excreted (7). Vitamin D2 
undergoes similar metabolism and catabolism to vitamin 
D3 through similar pathways (6). 
Loss-of-function mutations in CYP24A1 inhibit 
the breakdown of 25(OH)D3, 25(OH)D2, 1,25(OH)2D3 
and 1,25(OH)2D2 leading to an accumulation of active 
vitamin D metabolites and consequent hypercalcaemia 
(8), nephrocalcinosis and nephrolithiasis (9). Therefore, 
mutations in CYP24A1 should be considered as a potential 
cause of vitamin D-mediated parathyroid hormone 
(PTH)-independent hypercalcaemia. To date, cases of 
both adults and children with CYP24A1 mutations and 
hence increased sensitivity to vitamin D loading have 
been reported. Classically, infants tend to present with 
hypercalcaemia (10), whereas older children and adults 
usually present with nephrolithiasis, hypercalciuria and 
nephrocalcinosis (11) with hypercalcaemia and suppressed 
PTH. We recently identified a 32-year-old pregnant female 
(G1P0) who presented with symptomatic hypercalcaemia, 
hypercalciuria, hypervitaminosis D and suppressed intact 
PTH (iPTH). Symptom onset occurred at 17 weeks of 
gestation coinciding with trimester 2 of pregnancy. DNA 
sequencing identified two CYP24A1 variants. 
This study aimed to characterize the clinical and 
biochemical phenotypes of a family with heterozygous 
and compound heterozygous variants in CYP24A1 
following identification of two variants in the proband 
and to describe the proband’s unique presentation.
Methodology
Ethical approval for this study was granted by the 
Research Ethics Committee, Galway University Hospitals 
(Reference No – C.A. 1927; approval date 13-02-2018). 
Following informed written consent, DNA samples from 
the proband and the proband’s family were examined 
using targeted exon PCR of all coding exons of CYP24A1 
followed by Sanger sequencing. Clinical and biochemical 
phenotypes were correlated with CYP24A1 sequence 
information in the proband, her parents, siblings (n = 2), 
her daughter and two nephews. 
The proband (II.2) presented during the second 
trimester of a planned pregnancy with flu-like symptoms 
and was discovered following identification of 
asymptomatic hypercalcaemia on routine blood work. The 
proband (II.2), her father (I.1), mother (I.2), brother (II.1), 
sister (II.3), daughter (III.3) and two nephews (III.1, III.2) 
were recruited to this study. Detailed medical histories 
were recorded, and clinical examinations were performed. 
Family members had DNA samples tested for CYP24A1 
mutations by direct sequencing at the Northern Molecular 
Genetics Service, Newcastle upon Tyne, UK. Participants 
also had routine clinical biochemistry measured 
including calcium (Ca2+) (mmol/L), albumin (g/L), 
phosphate (mmol/L), vitamin D metabolites (25(OH)D, 
1,25(OH)2D, 24,25(OH)2D), iPTH, fibroblast growth factor 
23 (FGF-23), creatinine (estimated glomerular filtration 
rate (eGFR) using the CKD-Epidemiology Collaboration 
(CKD-EPI) formula (12)) and alkaline phosphatase (ALP) 
(U/L). Adult participants had urinary Ca2+ measured (spot 
and/or 24-hour urine collections). II.3 was unable to 
attend in person and only had DNA analysis for the 
CYP24A1 variants. II.1 and II.2 had serial measurements 
of Ca2+, 25(OH)D and iPTH.
Measurement of vitamin D metabolites
Serum 25(OH)D concentrations were measured using 
liquid chromatography tandem mass spectrometry 
(LC-MS/MS) on the Agilent HPLC 1290; Agilent 6460 
Triple quadrupole MS/MS in the Clinical Biochemistry 
Laboratory at Galway University Hospitals (ISO 
15189:2012 standards) (13, 14). Vitamin D was reported 
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as total serum 25(OH)D concentration (the sum of 
25(OH)D2 and 25(OH)D3 concentrations). The limits of 
quantification for 25(OH)D2 and 25(OH)D3 were 5 nmol/L 
and 8 nmol/L, respectively. Assay precision was ≤8.0% 
and bias was ≤5.0% at 25(OH)D2 levels of 42.2 nmol/L 
and 94.4 nmol/L and 25(OH)D3 levels of 39.9 nmol/L 
and 94.4 nmol/L. The Clinical Biochemistry Laboratory 
meets the performance targets set by the DEQAS (Vitamin 
D External Quality Assessment Scheme) advisory 
panel. Serum 24,25(OH)2D (total 24,25(OH)2D2 and 
24,25(OH)2D3) and serum 1,25(OH)2D (total 1,25(OH)2D2 
and 1,25(OH)2D3) were measured using LC-MS/MS on 
the Micromass Quattro Ultima Pt electrospray ionisation 
(ESI) tandem mass spectrometer (Waters Corp., Milford, 
MA, USA) at the Norfolk and Norwich University Hospital 
NHS Foundation Trust, Colney Lane, Norwich, UK (15). 
For serum 24,25(OH)2D2 and 24,25(OH)2D3, the limits of 
quantification were 0.1 and 0.8 nmol/L, respectively. The 
inter-assay coefficients of variability (CVs) for both serum 
24,25(OH)2D2 and 24,25(OH)2D3 were between 7.9 and 
11% (15). For 1,25(OH)2D, the limit of quantification was 
10 pmol/L with CVs of 8.0–13.0%.
Results
Clinical history: II.2 and III.3
The proband (II.2) presented during a planned pregnancy 
and was followed for 4 years. Of white European ethnicity, 
the proband was healthy, active and took over the counter 
(OTC) vitamin D supplements (1000 units per day; Protego 
Witamina D 100 food supplement and/or Mama DHA 
food supplement) for 2 months prior to conception. Past 
medical history included mitral valve prolapse (21 years 
previous), surgery for deviated nasal septum, migraine and 
abnormal liver function tests secondary to isotretinoin 
use for acne. She was an ex-smoker for 5 years (5 pack 
per year history). There was no alcohol consumption up 
to or during pregnancy. Previous laboratory tests were 
within normal range (adjusted (adj.) Ca2+ (reference 
interval (RI): 2.15–2.55 mmol/L). Serum 25(OH)D 
concentrations or other vitamin D metabolites were not 
previously measured.
 At 17 weeks of gestation, the proband attended 
her first antenatal visit. Clinical examination was 
unremarkable (blood pressure (BP) 122/78 mmHg). 
Electrocardiograph (ECG) was normal. Routine 
blood tests revealed elevated adj. Ca2+ (3.27 mmol/L 
(trimester-specific upper reference limit (URL): 
<2.30 mmol/L) with an ionized Ca2+ of 1.44 mmol/L 
(trimester-specific URL: 1.25 mmol/L), suppressed iPTH 
<6 ng/L (RI: 18–25 ng/L), elevated cholecalciferol (25(OH)D) 
264 nmol/L (URL: 55 nmol/L) and elevated calcitriol 
(1,25(OH)2D) 293 pmol/L (URL: <280 pmol/L) with evidence 
of hypercalciuria (Table 1). While undergoing an extensive 
workup for hypercalcaemia of pregnancy, the proband 
was treated aggressively with i.v. fluids with a resultant 
fall in Ca2+. Relevant negative laboratory indices included: 
parathyroid hormone-related protein (PTHrP) <1.0 pmol/L 
(RI: 0–1.8 pmol/L), lactate dehydrogenase (LDH) 100 U/L (RI: 
135–214 U/L), urine protein: creatinine ratio (PCR), serum 
protein electrophoresis (SPEP), serum free light chains 
(SFLC), urine protein electrophoresis (UPEP), vitamin A 
1.54 µmol/L (RI: 0.0–3.84 µmol/L) and calcitonin 1.0 ng/L 
(RI: 0.0–10.0 ng/L). Spot urine Ca2+: creatinine 
molar ratio and 24-hour urine Ca2+ were elevated at 
0.82 mmol/mmol (RI: 0.25–0.75 mmol/mmol) and 
9.85 mmol/24 h (RI: 0.30–6.9 mmol/24 h), respectively. 
Chest radiography, pelvis and thyroid echocardiography 
were unremarkable. Of note, abdominal ultrasound showed 
no evidence of urinary stone disease or nephrocalcinosis. 
The OTC vitamin D supplements which II.2 was taking 
prior to admission were examined and quantitated at the 
Public Analyst Laboratory Cork, Ireland (accredited service: 
ISO 17025). HPLC was the methodology used to determine 
the vitamin D content – Protego Witamina D 100 food 
supplement, vitamin D3, label 25 µg/capsule, result of 
analysis 27.5 µg/capsule; Mama DHA food supplement 
vitamin D3 label 25 µg/2 capsule, result of analysis 
16.8 µg/2 capsule.
During pregnancy, the proband was treated with a 
combination of i.v. fluids, a diet low in calcium and vitamin 
D and oral corticosteroids. II.2 required numerous prolonged 
hospital admissions to maintain Ca2+ levels within 
normal limits. The baby (III.3) had regular fetal scans with 
occipitofrontal diameter, head circumference, abdominal 
circumference and fetal weight within normal limits. At 3 
6+3 weeks of gestation, II.2 developed a headache with a BP of 
177/80 mmHg and commenced on labetalol 200 mg bd. At 
36+4 weeks of gestation, BP increased to 190/100 mmHg with 
clonus on clinical examination. Pre-eclampsia was diagnosed. 
She was given betamethasone and BP was managed with the 
addition of hydralazine peripartum. 
The baby (III.3) was delivered at 36+4 weeks of 
gestation by emergency C-section. III.3’s ionized Ca2+ 
was just above the upper limit of normal (1.35 mmol/L 
(RI: 1.15–1.33 mmol/L)). The baby was 
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alert with normal vitals (afebrile, heart 
rate 150 (100–159) b.p.m, respiratory rate 
50 (31–60) breaths per minute, oxygen 98 (>95)%. Placental 
histology, on microscopic examination of villi, pointed 
to segmental areas of impaired maternal blood flow 
within the placenta. However, this did not appear to have 
compromised the overall placental function in relation to 
fetal growth and oxygenation. Post-delivery, there was a 
spike in II.2’s adj. Ca2+ (3.29 (RI: 2.17–2.51) mmol/L) and 
ionized Ca2+ (1.35 (RI arterial: 1.15–1.28)mmol/L) (Fig. 
1A). This was aggressively treated with i.v. fluids and i.v. 
hydrocortisone followed by an oral prednisolone taper 
with a resultant normalisation of adj. Ca2+. Post-partum, 
BP remained difficult to control and required an increase in 
labetalol and the addition of nifedipine and methyldopa 
with a resultant normalisation in BP. Antihypertensives 
were tapered over time and eventually stopped – BP 
remained normal. II.2 developed an acute kidney 
injury post-delivery (eGFR decreased from a baseline 
63 mL/min/1.73 m2 to 44 mL/min/1.73 m2). Kidney 
function returned to baseline following aggressive 
hydration. Work-up for secondary hypertension 
revealed normal aldosterone:renin ratio and plasma 
metanephrines. Computerized tomography (CT) of thorax, 
abdomen and pelvis did not reveal any potential source of 
hypercalcaemia. At 3 months post-partum, the proband’s 
24,25(OH)2D and 25(OH)D measured 3.3 nmol/L 
Table 1 Demographics, clinical, biochemical and genetic analyses on first contact.
Parameter II.2a RIb II.2c I.1 I.2 II.1 II.3 RId III.1e III.2e III.3e
Age (years) 32 - 33 58 58 36 32 - 2 7 1
Gender (F/M) F - F M F M F - M M F
Mutation present A±B A/B - A/B A/A B A/B A/B - A A A
Total Ca2+ (mmol/L) 3.15 2.05–2.25 2.45 2.47 2.41 2.51  n/a 2.15–2.55 2.68 2.44 2.45
Adj. Ca2+ (mmol/L) 3.27 2.10–2.30 2.41 2.42 2.37 2.46  n/a 2.18–2.55  n/a  n/a  n/a
Albumin (g/L) 36 26–45 47 48 47 48  n/a 39–51 46 50 42
Phosphate (mmol/L) 1.04 0.87–1.48 0.93 1.37 1.2 1.1  n/a 0.87–1.45 1.61 1.46 1.81
iPTH (ng/L) <6 18–25 15.5 54.9 37.6 18  n/a 15–65 23.5 21.8 46.3
25(OH)D (nmol/L) 264 25–55 105 57 35 148  n/a 75–125 141 81 93
1,25(OH)2D (pmol/L) 293 72–280 83 125 94 143  n/a 55–139  n/a  n/a  n/a
24,25(OH)2D (nmol/L) n/a - 3.3 n/a n/a 2.1  n/a 1.3–13.5 (13)  n/a  n/a  n/a
25(OH)D:24,25(OH)2D ratio n/a - 32 n/a n/a 70  n/a 7–23 (13)  n/a  n/a  n/a
1,25(OH)2D:24,25(OH)2D ratio n/a - 25 n/a n/a 68  n/a 11–62  n/a  n/a  n/a
FGF-23 (RU/mL) n/a - 299 45 129 155  n/a <100  n/a  n/a  n/a
Creatinine (µmol/L) 90 35–71 94 111 82 102  n/a F: 49–90
M: 60–110
28 42 24
eGFR (mL/min/1.73 m2) 63 60–120 59 63 68 72  n/a 60–120  n/a  n/a  n/a
ALP (U/L) 51 25–126 35 72 55 68  n/a 35–104 367 235 263
fUr. Ca2+:creatinine molar ratio 0.82 0.25–0.75 n/a 0.21 0.21 n/a  n/a 0.25–0.75  n/a  n/a  n/a
Ur. Ca2+ (mmol/24h) 9.85 0.3–6.9 n/a  n/a  n/a 17.4  n/a 2.5–7.5  n/a  n/a  n/a
A or B, heterozygous; A, p.(Arg439Cys); A/A, homozygous; A/B, compound heterozygous, a17/40 weeks of gestation; B, p.(Trp275Arg); bspecific for 
trimester 2 of pregnancy; cindicates results from sample collected 3 months postpartum; dnon-pregnant adult; eall values for P6, P7 and P8 are within 
age-defined RIs; F, female; fspot/random urine sample; I.1, father; I.2, mother; II.1, brother; II.2, proband; II.3, sister; III.1, nephew; III.2, nephew; III.3, 
proband’s daughter; M, male; n/a, not available; RI, reference interval.
Figure 1
25(OH)D and adj. Ca2+ trends post presentation in the (A) proband (II.2) 
and (B) brother (II.1).
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(RI: 1.1–13.5 (15)) and 105 nmol/L, respectively, providing 
for an elevated 25(OH)D:24,25(OH)2D ratio of 32 (RI: 
7–23 (15)). While acknowledging that the magnitude 
of the 25(OH)D:24,25(OH)2D ratio was below currently 
published cut-offs (>50 and mostly >80), indicative 
of CYP24A1 mutations (16), the dual measurements 
(absolute 25(OH)D and 24,25(OH)2D concentrations) 
together with the abnormal 25(OH)D:24,25(OH)2D ratio 
warranted further investigation. As substrate depletion, 
bone disorders or pathological conditions associated 
with an increased concentration of FGF23 were not 
clinically implicated, follow-up examinations focused 
on 24-hydroxylase under activity and possible genetic 
abnormalities of CYP24A1. Sequencing of the proband’s 
DNA was carried out which revealed two CYP24A1 
genetic variants: R439C and W275R. The baby (III.3) was 
heterozygous for the known pathogenic mutation R439C.
II.2 is being followed closely in our outpatient 
department. II.2 has been advised to apply sunscreen daily, 
be cautious regarding sun exposure and keep hydrated. 
A dietician has prescribed a low calcium/vitamin D diet. 
The trends in II.2’s 25(OH)D and adj. Ca2+ are presented 
in Fig. 1A.
Clinical history: II.1, III.1 and III.2
The proband’s brother (II.1) presented as part of our familial 
screening program and was compound heterozygous for 
CYP24A1 variants: W275R and R439C. At his initial visit, 
II.1 had normal adj. Ca2+ (2.46 mmol/L), 24,25(OH)2D 
(2.1 nmol/L) and iPTH (18 ng/L) and elevated 25(OH)D 
(148 nmol/L), 25(OH)D:24,25(OH)2D ratio of 70 (RI: 7–23 
(15)), 1,25(OH)2D (143 pmol/L) and 1,25:24,25(OH)2D 
ratio of 68 (RI:11–62) (Table 2). The trends in II.1s 
25(OH)D and adj. Ca2+ over the following 12 months are 
presented in Fig. 1B. II.1 had intermittent hypercalcaemia 
with adj. Ca2+ between 2.51 and 2.65 mmol/L. Like II.2, 
he was advised to apply sunscreen daily, be cautious 
regarding sun exposure, keep hydrated and have a low 
calcium/vitamin D diet. His children III.1 and III.2 are 
heterozygous for the R439C mutation. 
Clinical history: I.1, I.2 and II.3 
Following enrolment in our study, the proband’s sister 
(II.3) was identified as being compound heterozygous 
with a history of nephrolithiasis during childhood for 
which no cause was identified. Following identification 
of her mutations, she presented with hypercalcaemia 
and nephrolithiasis during pregnancy to a hospital in 
a different country. The recent identification of her 
genotype facilitated rapid management. II.2’s mother (I.2) 
was heterozygous for the W275R variant and her father 
(I.1) was homozygous for the R439C mutation. Baseline 
laboratory indices were not indicative of hypercalcaemia 
or hypervitaminosis D (Table 1).
Table 2 Biochemical analyses and vitamin D metabolite profiling during follow-up: proband (II.2) and brother (II.1).
Parameter
Proband (aII.2) aII.1 Reference 
intervalF M
Month/year b05/16 04/17 06/17 11/18 05/19 05/16 07/17 -
Total Ca2+ (mmol/L) 2.45 2.50 2.53 2.59 2.54 2.51 2.65 2.15–2.55
Adj. Ca2+ (mmol/L) 2.41 2.51 2.49 2.55 2.52 2.46 2.60 2.17–2.51
Albumin (g/L) 47 44 47 47 46 48 48 39–51
Phosphate (mmol/L) 0.93 1.10 1.19 1.47 1.21 1.10 1.16 0.87–1.45
iPTH (ng/L) 15.5 <6.0 12.3 10.2 9.6 18.0 14.6 15–65
25(OH)D (nmol/L) 105 94 104 106 89 148 136 75–125
1,25(OH)2D (pmol/L) 83 124 135 101 124 143 192 55–139
24,25(OH)2D (nmol/L) 3.3 1.3 1.7 2.5 1.3 2.1 2.6 1.3–13.5
25(OH)D:24,25(OH)2D ratio 32 72 61 42 68 70 52 7–23
1,25(OH)2D:24,25(OH)2D ratio 25 95 79 40 95 68 74 11–62
FGF-23 (RU/mL) 299 n/a 216 n/a n/a 155 240 <100
Creatinine (µmol/L) 90 75 76 72 87 102 108 F: 49–90
M: 60–110
eGFR (mL/min/1.73 m2) 63 >90 88 >90 74 72 75 60–120
ALP (U/L) 51 46 48 37 43 68 72 35–104
cUr. Ca2+:creatinine molar ratio 0.82 n/a 1.32 n/a n/a n/a n/a 0.25–0.75
Ur. Ca2+ (mmol/24h) 9.85 n/a n/a n/a n/a 17.4 n/a 2.5–7.5
acompound heterozygous (A/B): A, p.(Arg439Cys); B, p.(Trp275Arg); eGFR was calculated using the Chronic Kidney Disease-Epidemiology Collaboration 
(CKD-EPI) formula; F, female; M, male; b3 months post-partum (not breastfeeding); n/a, not available; cspot/random urine sample.
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Genetic testing
Two heterozygous CYP24A1 missense variants were 
identified in the proband (II.2). R439C is a known 
pathogenic mutation resulting in a C to T transition in 
exon 10, c.1315C>T; p.(Arg439Cys) and was previously 
shown to be a loss of function mutation by site directed 
mutagenesis (16). W275R is a novel missense variant 
resulting in a T to C transition in exon 6, c.823T>C; 
p.(Trp275Arg) first identified by our group (15). The 
W275R variant is not previously reported in ClinVar 
(NIH Clinical Genomic Resource) or LOVD (Leiden 
Open Variation database) and is present at very 
low frequency in gnomAD and Exome Aggregation 
consortium (ExAC) public databases. Investigations into 
the pathogenicity of W275R show that the substitution 
occurs in a highly conserved amino acid within the 
protein domain of Cytochrome P450. An online genetic 
variant tool predictor (17) was used to grade the evidence 
accumulated for W275R. Variant classification was based 
on the American College of Medical Genetics (ACMG) 
Guidelines (18) and the Association for Clinical Genomic 
Science (ACGS) Best Practice Guidelines for Variant 
Classification (19). Predicted pathogenicity using in silico 
evidence (MutationTaster, Polyphen and SIFT) support a 
deleterious effect on the CYP24A1 protein (Fig. 2). Based 
on current evidence, the W275R variant is classified 
as likely pathogenic (class 4). Stronger evidence from 
functional studies or new cases will be required to upgrade 
its pathogenicity. Sanger sequencing of parental bloods 
confirmed the inheritance of both mutations in trans in 
the proband. The probands father (I.1) is homozygous for 
R439C and her mother (I.2) is heterozygous for the W275R 
mutation. Segregation analysis in other family members 
was performed. The family pedigree is presented in 
Fig. 3. Participants demographics, clinical and biochemical 
analyses on first contact and genotype are presented in 
Table 1. Of note, only the probands sister had a history of 
nephrolithiasis (II.3). 
Follow-up 25(OH)D:24,25(OH)2D ratio 
determinations in the proband (II.2) and 
brother (II.1)
A total of five separate 25(OH)D:24,25(OH)2D ratio 
determinations were performed on serum samples 
collected from the proband. The first was carried out at 
Figure 2
Evidence for CYP24A1 c.823T>C; p.(Trp275Arg) 
variant classification. The ACMG utilises a series 
of evidence criteria in support of a pathogenic (P) 
or benign (B) classification. The different types of 
evidence (functional, genetic, population, in-silico 
etc) are stratified according to the level of 
evidence (supporting, moderate, strong or very 
strong) and a pathogenicity classification 
(pathogenic, likely pathogenic, variant of unknown 
significance (VUS), likely benign or benign) 
assigned according to a set of ‘combined criteria’ 
provided in the guidelines (19). PM, moderate 
evidence of pathogenicity; PP, supporting 
evidence of pathogenicity. The level of evidence is 
then categorised numerically: PM1, located in 
functional domain; PM2, absent from controls; 
PM3, recessive disorder and present in trans with 
a pathogenic mutation; PP4, functional 
biochemical evidence; PP3, in silico evidence 
supporting pathogenicity.
Evidence for variant classification (ACMG code - level)
· The p.(Trp275Arg) variant is located in a highly conserved nucleotide and in a moderately 
conserved amino acid (across 12 species). It is located in the protein domain of 
cytochrome P450 (PM1).
· The p.(Trp275Arg) variant is present at very low frequency in Exome Aggregation 
Consortium (ExAC) and gnomAD public database (PM2).
· The Trp275Arg variant is detected in trans with a pathogenic variant (Arg439Cys) in a 
recessive disorder (PM3).
· Multiple lines of computational (in-silico) evidence support a deleterious effect on the 
gene. MutationTaster suggests the amino acid change is disease causing, Polyphen 
suggests it is probably damaging and SIFT predicts deleterious (PP3).
·
Gene CYP24A1
Variant description: HGVS NM_000782.4:c.823T>C p.(Trp275Arg)
Variant location: GRCh37 (hg19) Chr20(GRCh38):g.54164473A>G
Variant classification:
(Pathogenic/Likely Pathogenic/Uncertain 
Significance/Likely Benign/Benign
Likely Pathogenic (Class 4)
The patient’s phenotype is highly specific for a disease with a single genetic aetiology.
Biochemical evidence from the patient’s 25(OH)D: 24,25(OH)2D ratio is consistent with
inactivating CYP24A1 mutations in vivo [15, 16] (PP4).
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3 months post-partum and the remaining four over the 
following 3 years (Table 2). Of note, ratios in two of these 
five analyses were 32 and 42, respectively, and inconsistent 
with current criteria for biallelic CYP24A1 mutations (16). 
However, the remaining three 25(OH)D:24,25(OH)2D 
ratio results varied between 61 and 72 (Table 2) and are 
in keeping with published decision thresholds for biallelic 
CYP24A1 mutations (16). Furthermore, the proband’s 
brother (II.1), who harbours the same CYP24A1 genotype, 
had 25(OH)D:24,25(OH)2D ratios measured on two 
occasions and both results were consistent with published 
cut-offs indicative of biallelic CYP24A1 mutations (16). 
Biochemical results, together with the population data 
and in silico assessment (see Fig. 2), support the contention 
that this novel W275R variant is likely a mutation and 
not a polymorphism.
Discussion
This study reports two CYP24A1 mutations R439C and 
W275R identified in a pregnant female during the second 
trimester. The proband’s father (I.1) was homozygous 
for the R439C pathogenic mutation but did not have 
hypercalcaemia, which may be due to the variable 
penetrance of this mutation together with external 
factors that mitigate the development of hypercalcemia, 
such as dietary calcium intake, vitamin D levels, volume 
status and so on. Family members who were compound 
heterozygous for R439C and W275R mutations had 
hypercalcaemia and elevated concentrations of vitamin D 
metabolites. Only one family member had nephrolithiasis. 
The proband first presented during pregnancy, suggesting 
that patients with CYP24A1 mutations can maintain 
normal Ca2+ levels during steady state but may develop 
hypercalcaemia with the challenge of pregnancy when 
1,25(OH)2D levels are physiologically elevated. Variable 
presentations and severity of CYP24A1 mutations have 
been reported with only eight cases reported during the 
perinatal period (Table 3) (11, 16, 20, 21, 22, 23, 24, 25). 
Vitamin D is essential for calcium homeostasis and 
bone metabolism (2). Calcium homeostasis is altered in 
normal pregnancy (24). In healthy women, total 1,25-
(OH)2D levels were more than double early in pregnancy 
due to increased production of renal and placental 1-α 
hydroxylases (26) and remained elevated until the end of 
pregnancy. In addition, the absorption of calcium from the 
intestine more than doubles and bone resorption occurs 
to provide calcium for breast milk (27). Hypercalcaemia 
is exacerbated in pregnant women with inactivating 
CYP24A1 mutations and is normally associated with 
1,25(OH)2D levels in the upper normal range or slightly 
raised and concentrations of 25(OH)D that can be low, 
normal or mildly elevated (28). Vitamin D supplements 
recommended during pregnancy have the potential to 
aggravate hypercalcaemia in women with loss-of-function 
CYP24A1 mutations. The vitamin D supplements taken by 
the proband during pregnancy likely explain the markedly 
elevated 25-hydroxyvitamin D concentration observed at 
presentation. Castanet et  al. reported that a child who 
received higher dose vitamin D supplements (1900 U/day) 
as a baby developed hypercalcaemia, hypercalciuria 
and resultant nephrocalcinosis compared to his brother 
who only received 400 U/day – both had a homozygous 
CYP24A1 mutation (29) – suggesting that vitamin D 
dose may have an effect. Careful consideration should 
be given to the dosage of vitamin D supplementation 
and to monitoring adj. Ca2+ and vitamin D levels in 
pregnant females.
As highlighted by our case (II.2), investigation of 
non-PTH mediated hypercalcaemia remains challenging, 
especially in pregnancy. The commonest causes (90%) of 
hypercalcaemia are hyperparathyroidism and malignancy 
(30). The other 10% of cases result from hypercalcaemia 
related to vitamin D (granulomatous disease and vitamin D 
intoxication), endocrine disorders such as thyrotoxicosis, 
medications (thiazide diuretic, milk-alkali syndrome and 
vitamin A), renal (acute renal failure, chronic renal failure 
Figure 3
Family pedigree showing inheritance of CYP24A1 mutations. Arrow 
indicates the position of the proband in the family. I.1, father; I.2, mother; 
II.1, brother; II.2, proband; II.3, sister; III.1, nephew; III.2, nephew; III.3, 
proband’s daughter.
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or renal transplant) or other rarer causes such as CYP24A1 
mutations. The choice of imaging modality is limited 
in pregnancy as ionizing radiation poses risks to both 
mother and fetus (31). Therefore, initial investigations are 
typically biochemical and haematological. PTH related 
peptide (PTHrP) is raised in humoral hypercalcaemia 
of malignancy (32). In the context of low PTHrP, 
measurement of 1,25(OH)2D can be used to screen for 
vitamin D-mediated hypercalcaemia which can be seen 
with lymphoma. If both PTHrP and 1,25(OH)2D levels are 
low, hypercalcaemia secondary to osteolytic metastases 
should be considered (32). There is often a considerable 
delay in obtaining PTHrP or 1,25(OH)2D results as they 
are usually only performed in specialised centres. When 
there is clinical suspicion of malignancy, imaging 
(typically CT) or invasive procedures, such as bone 
marrow biopsy, can be required to identify the source. 
Delaying such investigations (a risk benefit analysis is 
required in pregnancy) contributes to anxiety and stress 
in the pregnant female. 
The utility of the ratio of serum 25(OH)D to 
24,25(OH)2D concentration has been promulgated as 
a useful biochemical screening tool to assess vitamin D 
catabolic status. Persistent hypercalcaemia together with 
a suppressed PTH, elevated 1,25(OH)2D level and a raised 
25(OH)D:24,25(OH)2D ratio are consistent with a CYP24A1 
loss-of-function mutation (33). Molin et  al. suggest that 
a 25(OH)D:24,25(OH)2D ratio of >50 and usually >80 
is indicative of inactivating CYP24A1 mutations in vivo 
(16). Previous work reveals that patients with biallelic 
CYP24A1 pathogenic variants have a significantly 
elevated ratio, whether they exhibit hypercalcemia or 
not (16). In the current study, the proband had 25(OH)D: 
24,25(OH)2D ratios measured on five occasions and in 
two, the ratio while above the reference interval of 23, 
were well below published cut-offs indicative of biallelic 
CYP24A1 mutations. We can only surmise that the 
observed fluctuations in the ratio occurred in tandem 
with the proband adhering to medical advice: minimizing 
unprotected/direct exposure to sunlight and avoiding 
diets rich in vitamin D or vitamin D supplements. 
Identifying CYP24A1 variants, as in II.3 pre-pregnancy, 
facilitates a more nuanced approach to the management 
of hypercalcaemia. 
Consensus regarding the management of 
hypercalcaemia secondary to CYP24A1 pathogenic 
variants during pregnancy (or indeed hypercalcaemia 
during pregnancy due to other causes) do not currently 
exist. Based on our experience and reports in other case 
studies, for patients with known CYP24A1 pathogenic 
variants considering pregnancy, we advocate avoiding 
supplements containing vitamin D or calcium, avoiding 
calcium bicarbonate, remaining well hydrated, generous 
daily application of sunscreen and reduced exposure to 
sunshine. Referral to a dietician for advice on a low calcium 
and vitamin D diet is recommended. Close monitoring 
of adj. Ca2+, 25(OH)D and iPTH before, during and after 
pregnancy is essential. If Ca2+ remains elevated, aggressive 
hydration with i.v. fluids (saline) is recommended. There 
are several reports on the use of oral corticosteroids in 
managing hypercalcaemia due to CYP24A1 pathogenic 
variants during pregnancy (22); they may be of benefit 
as they inhibit 1-α-hydroxylase conversion of 25(OH)D 
to 1,25(OH)2D thereby lessening intestinal calcium 
absorption (34). Calcitonin has been used cyclically (22) or 
as a single dose (23); calcitonin decreases hypercalcaemia 
by inhibiting osteoclast activity, enhances renal excretion 
of calcium (35) and does not cross the placenta (27). There 
are limited reports on the use of cinacalcet (36, 37) and 
bisphosphonates (38, 39, 40, 41, 42) during pregnancy 
or for treatment of hypercalcaemia of pregnancy due 
to other causes. Regarding bisphosphonates, Losada 
et  al. reported that 20% of children of women treated 
with bisphosphonates close to or during pregnancy had 
congenital malformations (42); therefore, their use in 
pregnancy cannot be recommended.
Rifampicin (43), ketoconazole (44, 45, 46) and 
fluconazole (47) have been reported as successful 
treatments for hypercalcaemia due to CYP24A1 mutations 
in the non-pregnant state. Rifampicin has been used to 
treat tuberculosis during pregnancy (48); however, there 
are no reports on its effectiveness or safety in treating 
hypercalcaemia during pregnancy. Depending on the dose 
and duration of treatment, ketoconazole and fluconazole 
are potentially teratogenic and should only be used if 
the benefit to the fetus clearly outweighs the risk (49). 
Regarding any pharmacotherapy, a risk benefit analysis 
must be undertaken on a patient-by-patient basis. 
Most laboratory systems do not have the digital 
functionality to deal with appropriate RIs in pregnancy. At 
our institution, the RI for total Ca2+ is 2.18 to 2.55 mmol/L 
in males and non-pregnant females. In pregnancy, this 
changes to 2.10–2.30 mmol/L during the second trimester 
and 2.05–2.43 mmol/L during the third trimester. In 
non-pregnant females, RIs are typically compiled from 
the local population at each institution. This is not the 
case for RIs in pregnancy. Robust trimester specific RIs 
for PTH and vitamin D metabolites are not available. In 
the absence of appropriate RIs associated with laboratory 
results for each trimester, the physician could potentially 
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miss mild elevations in adj. Ca2+ and, therefore, miss 
the opportunity to instigate appropriate management 
strategies at an early stage. 
Conclusions
In this family, only patients with the compound 
heterozygous mutations (R439C/W275R) had elevated 
Ca2+ and vitamin D metabolites, while only the 
proband’s sister had nephrolithiasis. The proband 
became symptomatic during pregnancy, suggesting 
that these mutations may be associated with a variable 
phenotype or incomplete penetrance, supporting the 
view that pregnancy can unmask an otherwise ‘silent 
genetic disorder’. Hypercalcaemia due to CYP24A1 
mutations in pregnancy may be associated with late onset 
hypertension/pre-eclampsia and warrants further study 
to determine causation. Accurate variant classification is 
critical as interpretation impacts directly on both patient 
and family care/management. Hypercalcaemia due to 
CYP24A1 mutations in pregnancy has also been associated 
with adverse maternal and baby outcomes in many of the 
reported cases and necessitates aggressive management. 
Our case highlights the difficulties associated with the 
investigation and management of hypercalcaemia in 
pregnancy and the importance of vitamin D profiling 
and genetic testing to investigate kindred of patients with 
known CYP24A1 mutations. Of importance, for positive 
mother and baby outcomes, all laboratory systems should 
as a rule and not as an exception have the appropriate 
digital functionality to deal with RIs in pregnancy. 
Identifying even a mild elevation in Ca2+ early in the 
gestation period can prevent or lessen the complications 
associated with hypercalcaemia for mother and baby.
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